Below are all the abstracts related to ROS1 NSCLC listed in the scientific program for the 2019 IASLC World Conference on Lung Cancer in Barcelona, Spain September 7-10. While the times and locations of sessions may change, the numbers and names will not. ES14 – What First Line in Oncogene Addicted NSCLC 15:15 – 16:45 … Continue reading ROS1 abstracts at #WCLC19
One of the founders of the ROS1ders, Janet Freeman-Daily, shares her story and why she advocates for molecular testing, clinical trials, and the positive changes she’s seen. “Given that lung cancer patients often don’t have much tumor tissue, we should make the best use of it, and running an NGS test is the best chance … Continue reading Advocating for ROS1
Members of The ROS1ders will be attending The International Association for the Study of Lung Cancer’s (IASLC) annual World Conference on Lung Cancer (WCLC) in Toronto, Canada, September 23-26, 2018. The Twitter hashtag for the conference is #WCLC2018. Presentations that will mention ROS1+ cancer are listed below. The abstract book containing these and other WCLC … Continue reading Presentations on ROS1+ Cancer at IASLC #WCLC2018
“No testing methodology demonstrated 100% sensitivity in the detection of ROS1 rearrangements or fusions among patients with non-small cell lung cancer, according to study results.” “The main point is just to be aware of the deficiencies in these assays and not to always trust a negative result from a single test,” Kurtis D. Davies, PhD, … Continue reading Detection of ROS1 rearrangement in lung cancer remains “complex”
This event is produced by the International Association for the Study of Lung Cancer (IASLC). For more information and to register for the webinar, visit IASLC’s webinar registration page. If you are unable to participate in the webinar in real time, you can view the video on IASLC’s webinar page a few days after the webinar concludes.
An 2018 update to the lung cancer molecular testing guideline says testing for ROS1 rearrangements is strongly recommended for all lung cancer patients regardless of clinical characteristics. The article “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” was published online January 23, 2018, in the Journal of … Continue reading Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC